ArriVent stock tumbles 60% after trial misses primary endpoint
ArriVent BioPharma's (AVBP) stock dropped 63% after its Phase 3 FURVENT trial for firmonertinib failed to meet the primary endpoint of progression-free survival in NSCLC patients. The trial compared two doses of firmonertinib against chemotherapy, with neither dose achieving statistical significance. Secondary endpoints showed some clinical benefit, but the company expressed disappointment in the results. The trial enrolled 398 patients globally.
How this was made
The 30-second read
Why it matters
The miss of the primary endpoint is a material negative catalyst, likely driving a sharp sell‑off and heightened volatility.
Market read
AVBP shares fell 63% on the news; the event is the primary driver of the article's relevance.
What to watch
Potential for partnership or licensing deals that could offset trial disappointment.
Background
ArriVent BioPharma (NASDAQ:AVBP) focuses on EGFR exon 20 insertion mutant NSCLC therapies. The FURVENT trial was its lead late‑stage study.
Ticker impact
ArriVent BioPharma disclosed that its Phase 3 FURVENT trial failed to meet the primary endpoint, causing a 63% share drop.
likely further pressure as investors price in the lack of efficacy data
First public disclosure of pivotal trial results for a mid‑cap biotech typically triggers sharp sell‑offs.
Market effects
May weigh on other EGFR‑targeted biotech stocks and raise caution on similar late‑stage trials.
Limited to US biotech sector; no broader regional effect.
Low global impact beyond the niche oncology biotech space.
Counterpoint
If the company can demonstrate overall survival benefit, the stock could rebound on future data.
Key entities
- ExecutiveBing Yao
Chairman and CEO of ArriVent BioPharma, quoted on trial results.
